OncLive
OncLive SOSS

Most Recent

Sacituzumab Govitecan Meets Primary End Point in Phase 3 ASCENT Trial

July 6th 2020

By Kristi Rosa

The novel antibody-drug conjugate sacituzumab govitecan-hziy demonstrated significant improvement in survival in patients with triple-negative breast cancer without brain metastases who previously received at least 2 prior therapies for metastatic disease.

Palliative Care Builds Bridges in Oncology Practice

July 6th 2020

By Toby Campbell, MD, MSCI

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

By Brittany Cote

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

By OncLive Staff

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

FDA Lifts Partial Clinical Hold on Camidanlumab Tesirine R/R Hodgkin Lymphoma Trial

July 6th 2020

By Kristi Rosa

The FDA has lifted a partial clinical hold that was placed on the phase 2 clinical trial of camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma.

Latest Videos

IMpower133 and CASPIAN Trials for Extensive Stage SCLC
IMpower133 and CASPIAN Trials for Extensive Stage SCLC
Dr. Chaft on Predictive Biomarkers in Lung Cancer
Dr. Chaft on Predictive Biomarkers in Lung Cancer
Antibody Drug Conjugates and Interstitial Lung Disease Risk
Antibody Drug Conjugates and Interstitial Lung Disease Risk
Exploring CAR T-Cell Therapy During The COVID-19 Pandemic
Exploring CAR T-Cell Therapy During The COVID-19 Pandemic

Featured Content

All Content

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

July 6th 2020, 8:17pm

By Andrew Yee, MD

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

Dr. Munshi on Next Steps With Idecabtagene Vicleucel in R/R Multiple Myeloma

July 6th 2020, 8:13pm

By Nikhil C. Munshi, MD

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Bach on the Rationale to Conduct a Systematic Review of ctDNA in CRC

July 6th 2020, 6:15pm

By Sander Bach, MD, PhD

Sander Bach, MD, PhD, ​discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Munshi on T-Cell Persistence With Ide-Cel in R/R Multiple Myeloma

July 6th 2020, 6:00pm

By Nikhil C. Munshi, MD

Nikhil C. Munshi, MD, discusses T-cell persistence with ​idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Optimal Sequence of Immunotherapy and Radiation Could Prolong Survival in Melanoma With Brain Metastases

July 6th 2020, 4:17pm

By Brittany Cote

A possible optimal sequence of radiation therapy and immune checkpoint inhibitors could help to prolong the survival of patients with melanoma who have brain metastases following surgical resection.

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

July 6th 2020, 2:32pm

By Matthew S. Davids, MD, MMSc

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Dr. Ghia on Updated ASCEND Trial Results in Relapsed/Refractory CLL

July 6th 2020, 2:10pm

By Paolo Ghia, MD

Paolo Ghia, MD, PhD, discusses updated results from the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Venetoclax/Azacitidine Slated as New Standard in Older Patients With AML Ineligible for Intensive Therapy

July 6th 2020, 1:54pm

By Erica DiNapoli

Courtney D. DiNardo, MD, MSCE, discusses the results of the study evaluating the combination of azacitidine plus venetoclax in elderly patients with AML.

Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast Cancer

July 6th 2020, 1:26pm

By Sylvia Adams, MD

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.

Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

July 6th 2020, 1:10pm

By Thomas Hope, MD

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

x